Hyperphosphatemia
Conditions
Keywords
Hyperphosphatemia, BE, Granule, Healthy volunteers
Brief summary
The study is conducted as a randomized, non-blinded, 2-way crossover study. Target population is 60 Japanese healthy male adult subjects selected by screening examination which will be conducted within 4 weeks before the first drug administration of period 1 (before the hospitalization of period 1). Subjects will admit in the clinical institute on Day -3 and be discharged on Day 6 in each period. During hospitalization, standardized phosphate diet from Day -2 to Day 4 will start approximately 20 minutes before dosing. Subject will take about 1300 mg of phosphate evenly at breakfast lunch and dinner for each day. Subject should consume at least 95% of a meal. Distilled water not to include phosphate will be used for drinking water and meal. Subjects are to drink at least 1 L of distilled water every day in clinic to make sure enough urine volume. The 24 hours urine collection will be conducted between Day -2 and Day 4 to investigate the urinary phosphate excretion.BAY77-1931 granule 500 mg or Fosrenol chewable tablet 500 mg will be administered three times daily after each meal from Day 1 to Day 4. On day 4 single dose after breakfast will be administered. Study drugs will be administered immediately after each meal, that is within 20 minutes after start of each meal with 240 mL of distilled water. A Fosrenol chewable tablet 500 mg will be taken after chewing completely.
Interventions
DRUGLanthanum Carbonate (Fosrenol, BAY77-1931) Granule
BAY77-1931 Granule TID for 4 days
DRUGLanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
BAY77-1931 Chewable tablet TID for 4 days
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Japanese male volunteers who must have given their written informed consent to participate in the study * Age is between 20 and 45 years * Body Mass Index (BMI) is between 17.6 and 26.4 kg/m2. * Volunteers who are judged by the investigators to be suitable for enrollment in this clinical trial based upon the data from a screening test.
Exclusion criteria
* A history of relevant diseases of internal organs (diseases that may significantly jeopardize body systems, such as severe liver or renal dysfunction, active peptic ulcer, ulcerative colitis, Crohn's disease, narrowing of colon lumen) or, of the central nervous system (e.g., epilepsy), or other organs which are likely to show inappropriateness for participation in this study * Conditions of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator (mental diseases that are thought to be ineligible for the communal life in the study participation, unable to consent to the participation, disables) * Known drug hypersensitivity or idiosyncrasy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioequivalence based on daily urinary phosphate excretion | Follow up examination cunducted on 7 to 10 days after the last drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event collection | Follow up examination cunducted on 7 to 10 days after the last drug administration |
Countries
Japan
Outcome results
None listed